Largest biotech companies by cash on hand
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Amgen leads the 24 biotech companies ranked by cash on hand, at ZAR 157.7B, ahead of BioNTech (ZAR 147.1B) and Gilead Sciences (ZAR 130.7B). Figures as of 18 Nov 2026, 21:41 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenZAR 157.7B
- Median
- ZAR 7.5B
- Combined market value
- ZAR 14.45T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Cash on hand ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | ZAR 157.7B | ZAR 4.15T | ZAR 7,667.98 | 3.07% down | 34% up | ||
| 2 | BioNTechBNTX · Health Care | ZAR 147.1B | ZAR 356.6B | ZAR 1,438.27 | 1.89% down | 16% down | ||
| 3 | Gilead SciencesGILD · Health Care | ZAR 130.7B | ZAR 3.62T | ZAR 2,919.05 | 0.75% down | 33% up | ||
| 4 | argenxARGX · Health Care | ZAR 60.3B | ZAR 1.02T | ZAR 16,259.62 | 0.66% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | ZAR 52B | ZAR 642B | ZAR 4,342.98 | 0.25% up | 49% up | ||
| 6 | ModernaMRNA · Health Care | ZAR 44.8B | ZAR 1.38T | ZAR 3,399.45 | 4.84% down | 755% up | ||
| 7 | ImmunovantIMVT · Health Care | ZAR 15.6B | ZAR 118.6B | ZAR 573.00 | 0.12% down | 43% up | ||
| 8 | QiagenQGEN · Health Care | ZAR 14.5B | ZAR 176.8B | ZAR 856.12 | 0.38% down | 12% up | ||
| 9 | Neurocrine BiosciencesNBIX · Health Care | ZAR 12.3B | ZAR 284.8B | ZAR 2,813.33 | 1.84% down | 20% up | ||
| 10 | RepligenRGEN · Health Care | ZAR 9.8B | ZAR 190.7B | ZAR 2,982.79 | 6.47% up | 5% up | ||
| 11 | Krystal BiotechKRYS · Health Care | ZAR 8.6B | ZAR 161.4B | ZAR 5,447.34 | 5.62% up | 46% up | ||
| 12 | ExelixisEXEL · Health Care | ZAR 8.3B | ZAR 287.9B | ZAR 1,179.68 | 0.31% down | 63% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | ZAR 6.6B | ZAR 597.1B | ZAR 2,760.81 | 1.76% down | 131% up | ||
| 14 | Kymera TherapeuticsKYMR · Health Care | ZAR 6.2B | ZAR 178.6B | ZAR 2,092.46 | 0.32% down | 87% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | ZAR 6B | ZAR 67.3B | ZAR 694.26 | 0.10% up | 21% down | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | ZAR 5.6B | ZAR 101.2B | ZAR 829.18 | 6.48% up | 14% up | ||
| 17 | Bio-TechneTECH · Health Care | ZAR 4.6B | ZAR 197.4B | ZAR 1,256.72 | 0.17% up | 26% up | ||
| 18 | Kodiak SciencesKOD · Health Care | ZAR 3.6B | ZAR 110.5B | ZAR 1,689.62 | 1.04% up | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | ZAR 3.2B | ZAR 137B | ZAR 2,009.89 | 3.88% up | 340% up | ||
| 20 | VaxcytePCVX · Health Care | ZAR 3B | ZAR 160B | ZAR 1,010.90 | 1.48% down | 22% up | ||
| 21 | Halozyme TherapeuticsHALO · Health Care | ZAR 2.3B | ZAR 188.7B | ZAR 1,654.90 | 0.18% down | 37% up | ||
| 22 | ImmunityBioIBRX · Health Care | ZAR 1.5B | ZAR 123.1B | ZAR 115.74 | 7.03% up | 193% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | ZAR 1.2B | ZAR 79.6B | ZAR 491.63 | 0.11% down | 88% up | ||
| 24 | CG OncologyCGON · Health Care | ZAR 561.2M | ZAR 123.4B | ZAR 1,381.96 | 1.34% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Cash on hand is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 17.2745 ZAR).
Questions and answers
Which biotech companies rank first by cash on hand?
Amgen (ZAR 157.7B), BioNTech (ZAR 147.1B) and Gilead Sciences (ZAR 130.7B) are the top three of the 24 biotech companies ranked by cash on hand as of 18 Nov 2026, 21:41 UTC.
How many biotech companies are in this ranking?
24 are ranked by cash on hand.
What are these biotech companies worth together?
The 24 biotech companies ranked by cash on hand have a combined market value of ZAR 14.45T as of 18 Nov 2026, 21:41 UTC.
What does ranking by cash on hand measure?
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by cash on hand”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=cash-on-hand
Underlying data: Yahoo Finance; SEC EDGAR.